#Sweden #Orexo #Abera #AmorphOX #Uppsala

Orexo and Abera Join Forces for Nasal Powder Vaccine Development

Orexo AB, a leading Swedish pharmaceutical firm, has recently announced an exciting collaboration with Abera Bioscience to develop nasal powder vaccines utilizing its cutting-edge AmorphOX technology. This strategic partnership marks a key step in Orexo’s goal to expand the applications of its innovative powder-based drug delivery methods.

The AmorphOX technology is designed to enhance the stability and effectiveness of various active ingredients, including larger biomolecules such as vaccines. With its proven capabilities, AmorphOX aims to provide more reliable methods for drug administration, shifting away from traditional approaches that may not be as effective.

Abera, on the other hand, brings its extensive expertise in mucosal vaccines, having dedicated over three decades to research in fields such as molecular biology and microbiology. This combination of Orexo’s advanced technology and Abera’s vaccine development experience promises to pave the way for breakthrough innovations in the pharmaceutical landscape.

Focus on Influenza Vaccine

At the forefront of this collaboration is the intent to develop powder-based intranasal vaccine candidates, specifically highlighting Abera’s influenza vaccine development. Influenza poses a significant threat globally, with seasonal outbreaks causing widespread health issues. The need for effective vaccination strategies has never been more crucial, particularly in light of potential pandemic scenarios.

As stated by Maria Alriksson, the CEO of Abera, “Reflecting on the current landscape, influenza represents a major public health challenge. The innovative powder formulations produced by Orexo complement our capabilities significantly, and together, we can unlock the vast potential lying in this realm.”

Research indicates that an intranasal influenza vaccine could not only enhance vaccine efficiency but also offer a straightforward and less invasive alternative for patients seeking to mitigate infection risks. Such a method could be integral in curtailing the spread during future outbreaks or pandemics.

Funding and Strategic Vision

The collaboration is primarily driven by funding from Abera, backed by numerous grants, including support from CEPI (the Coalition for Epidemic Preparedness Innovations). This financial foundation underscores the importance of their joint venture in public health advancements, especially in preparing for potential future viral crises.

Robert Rönn, Orexo's SVP and Head of Research and Development, expresses optimism about this collaboration, stating, “Working with Abera aligns seamlessly with our strategic vision to develop the AmorphOX platform further. It allows us to demonstrate the versatility and value of our technology while contributing to global health security.”

About Orexo and AmorphOX

Orexo has established a robust reputation within the industry for its commitment to addressing critical medical needs through proprietary formulation technologies. Over the last thirty years, the company has developed innovative treatments primarily targeting opioid use disorders while also extending its portfolio across various therapeutic areas.

Highlighted within this development is the AmorphOX platform, a unique combination of drug materials that form a powdered composition. This technology showcases four key benefits: chemical stability, physical stability, rapid dissolution, and versatility across a wide range of active drug ingredients. Its efficacy has been validated by several clinical studies involving human participants, setting a high standard for future developments.

About Abera Bioscience

Founded in 2012, Abera Bioscience is committed to pioneering vaccine solutions forwarding public health objectives through its unique BERA™ vaccine platform. This platform is predicated on bacterial particles that serve as effective carriers for antigens, aiming to provide both local and systemic immunity. Their recent advancements in research position them at the cutting edge of vaccine development, with particular attention to the urgent needs in pandemic preparedness.

The partnership between Orexo and Abera not only exemplifies a dynamic response to modern health challenges but also symbolizes a commitment to enhancing global vaccine strategies. As both companies embark on this journey, the potential outcomes from their collaboration could redefine the landscape of vaccine delivery methodologies, making a lasting impact on public health.